Goldman Sachs resumed coverage of Roivant Sciences (ROIV) with a Buy rating and $19 price target The firm is positive on a successful clinical outcome for the Phase 3 VALOR data.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- Roivant Sciences participates in a conference call with JPMorgan
- Roivant Sciences Announces $500M Share Repurchase Program
- Roivant Sciences announces $500M share repurchase program
- Optimistic Outlook for Roivant Sciences: Buy Rating Backed by Brepo’s Potential and Financial Opportunities
- Optimistic Outlook for Roivant Sciences Driven by Promising Brepocitinib Results in Phase 3 VALOR Study
